Key Drivers
- Strong liquidity
- Minimal revenue
- Large cash burn
AIAI Summary
Zenas has shifted into an event‑driven investment as obexelimab's positive Phase data plus imminent FDA/EMA filings and a structured up‑to‑$250M non‑dilutive facility materially shorten the path to value and curb immediate dilution, but the thesis remains binary—reliant on timely regulatory wins and tranche/covenant execution amid high cash burn.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Minimal revenue
- •Large cash burn
Despite a very strong liquidity position and low leverage, ZBIO is burning cash and incurring large operating losses on negligible revenue, creating a solvency buffer but severe profitability and cash‑flow risk.
Price Behavior
Key Price Behavior Insights:
- •Short-term downtrend
- •Below moving average
- •Support at $22.30
Last month the price fell about 14% from $25.88 to $22.30, trading ~10–11% below the last-month 21-day SMA near $25.00 (now resistance) with immediate support at $22.30—break below signals further downside, rebound suggests short-term stabilization.
Large jump from $15–16 to $34.50 on 2026-01-02 suggests corporate action or data issue
Sentiment & News
Key News Insights:
- •Obexelimab filings
- •$250M financing
- •ENAVATE stake
Zenas advanced obexelimab regulatory plans and broader autoimmune pipeline progress while securing up to $250M in non-dilutive financing and drawing a large investor stake.
The financing and investor buy-in reduce near-term funding risk and should support clinical execution and positive sentiment ahead of key trial readouts
Similar Companies in Healthcare
Other companies in the same sector with AI ratings